Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 70 of the 71 references it cites were found in a registry or an index.

Oral supplementation of healthy adults with 2′- O -fucosyllactose and lacto- N -neotetraose is well tolerated and shifts the intestinal microbiota

Open access
Elison, Emma, Vigsnaes, Louise K., Rindom Krogsgaard, Laura, Rasmussen, Julie, Sørensen, Nikolaj, McConnell, Bruce, Hennet, Thierry, Sommer, Morten O. A., Bytzer, Peter · 2016 · British Journal of Nutrition

Abstract

The gut microbiota has been established as an important player influencing many aspects of human physiology. Breast milk, the first diet for an infant, contains human milk oligosaccharides (HMO) that shape the infant’s gut microbiota by selectively stimulating the growth of specific bacteria, especially bifidobacteria. In addition to their bifidogenic activity, the ability of HMO to modulate immune function and the gut barrier makes them prime candidates to restore a beneficial microbiota in dysbiotic adults and provide health benefits. We conducted a parallel, double-blind, randomised, placebo-controlled, HMO-supplementation study in 100 healthy, adult volunteers, consuming chemically produced 2′- O -fucosyllactose (2′FL) and/or lacto- N -neotetraose (LNnT) at various daily doses and mixes or placebo for 2 weeks. All participants completed the study without premature discontinuation. Supplementation of 2′FL and LNnT at daily doses up to 20 g was shown to be safe and well tolerated, as assessed using the gastrointestinal symptoms rating scale. 16S rRNA sequencing analysis showed that HMO supplementation specifically modified the adult gut microbiota with the primary impact being substantial increases in relative abundance of Actinobacteria and Bifidobacterium in particular and a reduction in relative abundance of Firmicutes and Proteobacteria. This study provides the first set of data on safety, tolerance and impact of HMO on the adult gut microbiota. Collectively, the results from this study show that supplementing the diet with HMO is a valuable strategy to shape the human gut microbiota and specifically promote the growth of beneficial bifidobacteria.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1017/s0007114516003354

Cites

70 of 70 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Flow chart of the study. A total of 110 healthy, adult volunteers were screened for eligibility to participate in the study; 100 of them were randomised to one of the following intervention groups: 2′-O-fucosyllactose (2′FL), lacto-N-neotetraose (LNnT) or 2:1 mix of 2′FL:LNnT, each in three daily doses of 5, 10 or 20 g, or 2 g glucose as placebo. GSRS, gastrointestinal symptom rating scale.
Fig. 1 Flow chart of the study. A total of 110 healthy, adult volunteers were screened for eligibility to participate in the study; 100 of them were randomised to one of the following intervention groups: 2′-O-fucosyllactose (2′FL), lacto-N-neotetraose (LNnT) or 2:1 mix of 2′FL:LNnT, each in three daily doses of 5, 10 or 20 g, or 2 g glucose as placebo. GSRS, gastrointestinal symptom rating scale.CC BY · PubMed Central
Fig. 2 Gastrointestinal symptom rating scale (GSRS) scores at the end of the intervention. Scores ranged from 1 (no discomfort) to 7 (very severe discomfort). (a) 2′-O-fucosyllactose (2′FL) supplementation groups and placebo group; (b) lacto-N-neotetraose (LNnT) supplementation groups and placebo group; (c) 2′FL:LNnT (2:1) mix supplementation groups and placebo group. , 20 g, , 10 g, , 5 g, , placebo. GSRS scores at the end of intervention for placebo and the intervention group were compared using a two-way ANOVA and Bonferroni’s multiple comparisons correction. * Significantly different between the intervention group and the placebo group (P<0·05).
Fig. 2 Gastrointestinal symptom rating scale (GSRS) scores at the end of the intervention. Scores ranged from 1 (no discomfort) to 7 (very severe discomfort). (a) 2′-O-fucosyllactose (2′FL) supplementation groups and placebo group; (b) lacto-N-neotetraose (LNnT) supplementation groups and placebo group; (c) 2′FL:LNnT (2:1) mix supplementation groups and placebo group. , 20 g, , 10 g, , 5 g, , placebo. GSRS scores at the end of intervention for placebo and the intervention group were compared using a two-way ANOVA and Bonferroni’s multiple comparisons correction. * Significantly different between the intervention group and the placebo group (P<0·05).CC BY · PubMed Central
Fig. 3 Principal coordinates analysis plot of generalised UniFrac distances for all samples collected. (a) Before intervention and (b) after intervention. Phyla abundances are overlaid in blue. Samples are divided into intervention groups with the label at the centre of gravity for each group. Before intervention, there is no clear pattern. After intervention, the human milk oligosaccharide supplementation groups followed an axis of increasing Actinobacteria and decreasing Firmicutes for increasing doses.
Fig. 3 Principal coordinates analysis plot of generalised UniFrac distances for all samples collected. (a) Before intervention and (b) after intervention. Phyla abundances are overlaid in blue. Samples are divided into intervention groups with the label at the centre of gravity for each group. Before intervention, there is no clear pattern. After intervention, the human milk oligosaccharide supplementation groups followed an axis of increasing Actinobacteria and decreasing Firmicutes for increasing doses.CC BY · PubMed Central
Fig. 4 Relative abundance of faecal bacteria at the phylum level. (a and b) Phyla level in the three 2′-O-fucosyllactose (2′FL) groups receiving 5, 10 or 20 g and placebo before and after intervention; (c and d) phyla level in the three lacto-N-neotetraose (LNnT) groups receiving 5, 10 or 20 g and placebo before and after intervention; (e and f) phyla level in the three mix groups receiving 5, 10 or 20 g of 2′FL:LNnT (2:1) and placebo before and after intervention. * Significantly different between before and after intervention (P<0·05). , Actinobacteria; , Bacteroidetes; , Firmicutes; , Proteobacteria; , others.
Fig. 4 Relative abundance of faecal bacteria at the phylum level. (a and b) Phyla level in the three 2′-O-fucosyllactose (2′FL) groups receiving 5, 10 or 20 g and placebo before and after intervention; (c and d) phyla level in the three lacto-N-neotetraose (LNnT) groups receiving 5, 10 or 20 g and placebo before and after intervention; (e and f) phyla level in the three mix groups receiving 5, 10 or 20 g of 2′FL:LNnT (2:1) and placebo before and after intervention. * Significantly different between before and after intervention (P<0·05). , Actinobacteria; , Bacteroidetes; , Firmicutes; , Proteobacteria; , others.CC BY · PubMed Central
Fig. 5 Change in sequence abundance of Actinobacteria (a) and Bifidobacterium (b). The box represents the median and the 25th to 75th percentiles. The whiskers represent the smallest and largest changes observed. * Significantly different between the intervention group and the placebo group (P<0·05). 2′FL, 2′-O-fucosyllactose; LNnT, lacto-N-neotetraose; Mix, 2′FL:LNnT (2:1).
Fig. 5 Change in sequence abundance of Actinobacteria (a) and Bifidobacterium (b). The box represents the median and the 25th to 75th percentiles. The whiskers represent the smallest and largest changes observed. * Significantly different between the intervention group and the placebo group (P<0·05). 2′FL, 2′-O-fucosyllactose; LNnT, lacto-N-neotetraose; Mix, 2′FL:LNnT (2:1).CC BY · PubMed Central
Fig. 6 Change in sequence abundance of three operational taxonomic units (OTU) showing high similarity to the described Bifidobacterium species, B. adolescentis, B. longum and B. bifidum. The box represents the median and the 25th to 75th percentiles. The whiskers represent the smallest and largest changes observed. * Significantly different between the intervention group and the placebo group (P<0·05). 2′FL, 2′-O-fucosyllactose; LNnT, lacto-N-neotetraose; Mix, 2′FL:LNnT (2:1). , s1_r64; , s1_r2031; , s1_r379.
Fig. 6 Change in sequence abundance of three operational taxonomic units (OTU) showing high similarity to the described Bifidobacterium species, B. adolescentis, B. longum and B. bifidum. The box represents the median and the 25th to 75th percentiles. The whiskers represent the smallest and largest changes observed. * Significantly different between the intervention group and the placebo group (P<0·05). 2′FL, 2′-O-fucosyllactose; LNnT, lacto-N-neotetraose; Mix, 2′FL:LNnT (2:1). , s1_r64; , s1_r2031; , s1_r379.CC BY · PubMed Central
Fig. 7 Relative abundance of faecal bacteria at the genus level from before and after intervention. The eighteen genera, Bifidobacterium, Bacteroides, Barnesiella, Parabacteroides, Prevotella, Alistipes, Lactobacillus, Eubacterium, Blautia, Coprococcus, Dorea, Lachnospiracea incertae sedis, Roseburia, Faecalibacterium, Ruminococcus, Dialister, Escherichia/Shigella and Akkermansia, selected have been associated with obesity, irritable bowel syndrome or inflammatory bowel disease. (a) The mean of relative abundance of eighteen genera from the three intervention groups given 10 g of human milk oligosaccharide (HMO). (b) Relative abundance of eighteen genera from the placebo. Values are means, with their standard errors represented by vertical bars. Multiple t test was performed followed by a calculation of false discovery rate indicated as an adjusted P-value. * Significantly different between the groups (P<0·05). Lachn_inc_sedis, Lachnospiracea incertae sedis; , Before; , after.
Fig. 7 Relative abundance of faecal bacteria at the genus level from before and after intervention. The eighteen genera, Bifidobacterium, Bacteroides, Barnesiella, Parabacteroides, Prevotella, Alistipes, Lactobacillus, Eubacterium, Blautia, Coprococcus, Dorea, Lachnospiracea incertae sedis, Roseburia, Faecalibacterium, Ruminococcus, Dialister, Escherichia/Shigella and Akkermansia, selected have been associated with obesity, irritable bowel syndrome or inflammatory bowel disease. (a) The mean of relative abundance of eighteen genera from the three intervention groups given 10 g of human milk oligosaccharide (HMO). (b) Relative abundance of eighteen genera from the placebo. Values are means, with their standard errors represented by vertical bars. Multiple t test was performed followed by a calculation of false discovery rate indicated as an adjusted P-value. * Significantly different between the groups (P<0·05). Lachn_inc_sedis, Lachnospiracea incertae sedis; , Before; , after.CC BY · PubMed Central
Fig. 8 SCFA in faeces. Concentrations are given as mm/g faeces of acetate (a), butyrate (b) and propionate (c) in samples from each intervention group and placebo before () and after () intervention. The box represents the median and the 25th to 75th percentiles. The whiskers represent the smallest and largest concentrations measured. 2′FL, 2′-O-fucosyllactose; LNnT, lacto-N-neotetraose; Mix, 2′FL:LNnT (2:1).
Fig. 8 SCFA in faeces. Concentrations are given as mm/g faeces of acetate (a), butyrate (b) and propionate (c) in samples from each intervention group and placebo before () and after () intervention. The box represents the median and the 25th to 75th percentiles. The whiskers represent the smallest and largest concentrations measured. 2′FL, 2′-O-fucosyllactose; LNnT, lacto-N-neotetraose; Mix, 2′FL:LNnT (2:1).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 71 references

Cited by

See all 220

Metadata

Authors
Elison, E., Vigsnaes, L. K., Rindom Krogsgaard, L., Rasmussen, J., Sørensen, N., McConnell, B., Hennet, T., Sommer, M. O. A., & Bytzer, P.
Affiliations
  • University of Copenhagen (DK)
  • Clinical Microbiomics (Denmark) (DK)
  • University of Zurich (CH)
  • Novo Nordisk Foundation (DK)
Corresponding author
Elison, Emma
Venue
British Journal of Nutrition
Published
2016-10-10
Volume
116
Issue
8
Pages
1356-1368
ISSN
  • 0007-1145 (ISSN-L)
  • 1475-2662
OpenAlex
W2530574460
Cited by
218
References
71
Citations by year
2026: 23 · 2025: 35 · 2024: 25 · 2023: 23 · 2022: 22 · 2021: 28 · 2020: 24 · 2019: 19 · 2018: 11 · 2017: 8
FWCI
13.26
Type
journal article
Language
en
Open access
Locations
  • British Journal Of Nutrition (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, other-oa)
  • Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
  • Technical University of Denmark, DTU Orbit (Technical University of Denmark, DTU) (submittedVersion, cc-by)
  • Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
  • Zurich Open Repository and Archive (University of Zurich)
Funders
  • Lundbeckfonden (R77-2010-6772, R140-2013-13496)
  • Universität Zürich
  • Novo Nordisk Fonden (NNF13SA0009311, NNF13SA0006019, NNF14OC0011335, NNF10CC1016517)
Topics
  • Health Sciences › Nursing › Nutrition and Dietetics › Infant Nutrition and Health
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
  • Health Sciences › Nursing › Nutrition and Dietetics › Microbial Metabolites in Food Biotechnology
Keywords
human milk oligosaccharides, lacto-N-neotetraose, gut microbiota, bifidogenic activity, Bifidobacterium, actinobacteria, dietary supplementation, tolerability, healthy adults, 16S rRNA gene sequencing
MeSH terms
Bacillota, Firmicutes, Gastrointestinal Microbiome, Adult, Bifidobacterium, Denmark, Double-Blind Method, Feces, Female, Humans, Male, Middle Aged, Oligosaccharides, Trisaccharides, Biomarkers, Proteobacteria, Principal Component Analysis, Actinobacteria, Young Adult, Prebiotics, Molecular Typing, Dysbiosis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Oral supplementation of healthy adults with 2′- O -fucosyllactose and lacto- N -neotetraose is well tolerated and shifts the intestinal microbiota. https://app.cochat.ai/papers/10.1017/s0007114516003354
The paper
Elison, E., Vigsnaes, L. K., Rindom Krogsgaard, L., Rasmussen, J., Sørensen, N., McConnell, B., Hennet, T., Sommer, M. O. A., & Bytzer, P. (2016). Oral supplementation of healthy adults with 2′- O -fucosyllactose and lacto- N -neotetraose is well tolerated and shifts the intestinal microbiota. British Journal of Nutrition. https://doi.org/10.1017/s0007114516003354

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.